Preclinical investigation of [

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Sarah D Busslinger, Chiara Favaretto, Pascal V Grundler, Karl Johnston, Kristel Kegler, Ulli Köster, Ana Katrina Mapanao, Avni Mehta, Cristina Müller, Roger Schibli, Zeynep Talip, Nicholas P van der Meulen

Ngôn ngữ: eng

Ký hiệu phân loại:

Thông tin xuất bản: Germany : European journal of nuclear medicine and molecular imaging , 2025

Mô tả vật lý:

Bộ sưu tập: NCBI

ID: 189460

Thêm vào giỏ Liên kết toàn văn

PURPOSE: Terbium-149 is a short-lived α-particle emitter, potentially useful for tumor-targeted therapy. The aim of this study was to investigate terbium-149 in combination with the somatostatin receptor (SSTR) agonist DOTATATE and the SSTR antagonist DOTA-LM3. The radiopeptides were evaluated to compare their therapeutic efficacy in vitro and in vivo. METHODS: Terbium-149 was produced at ISOLDE/CERN and chemically purified at the Paul Scherrer Institute. Radiolabeling of somatostatin analogues with [ RESULTS: The radiolabeling of peptides was achieved at molar activities of up to 20 MBq/nmol at ≥ 98% radiochemical purity. AR42J cell viability was reduced in an activity-dependent manner, with [

Tạo bộ sưu tập với mã QR